Surfactant supplementation in the lung

Respiratory Care Clinics of North America

Volumn 8, Issue 2, 2002, Pages 211-236

  Anzueto, Antonio ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CORUSURF; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; PHOSPHOLIPID; SURFAXIN; VENTICUTE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; FEMALE; HUMAN; INFANT; LUNG; LUNG FUNCTION; LUNG GAS EXCHANGE; MALE; NEBULIZER; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; LUNG; PULMONARY GAS EXCHANGE; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 0035986977     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(02)00004-7     Document Type: Article

References (112)

1. Surface active materials from dog lung: Composition and physiological correlations
2. State of the art: Surfactant for the treatment of respiratory distress syndrome
3. Artificial surfactant therapy in hyaline membrane disease
4. A multicenter randomized controlled clinical trial of bovine surfactant for prevention of respiratory distress syndrome
5. Exogenous human surfactant for treatment of severe respiratory distress syndrome
6. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants
7. Double-blind randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome
8. Acute respiratory distress in adults
9. Characteristics of pulmonary surfactant in adult respiratory syndrome associated with trauma and shock
10. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome
11. Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol
12. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
13. The biology of surfactant
14. Surfactant and the adult respiratory distress syndrome
15. Metabolism and turnover of lung surfactant
16. Recycling of surfactant in black and beige mice: Pool sizes and kinetics
17. Subfractionation of lung surfactant. Implications for metabolism and surface activity
18. Surfactant subtypes in mice: Characterization and quantitation
19. Turnover of phospholipids isolated from fractions of lung lavage fluid
20. Alteration of molecular species of phosphatidylcholine from human pulmonary surfactant in severe pneumonia and idiopathic pulmonary fibrosis
21. Alveolar surfactant and adult respiratory distress syndrome: Pathogenetic role and therapeutic prospects
22. Alterations in alveolar surfactant following severe multiple trauma
23. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups
24. Pulmonary surfactant
25. Surfactant abnormalities and adult respiratory failure
26. Effect of smoking on the lipid composition of lung lining fluid and relationship between immunostimulatory lipids, inflammatory cells and foamy macrophages in extrinsic allergic alveolitis
27. Developmental expression of pulmonary surfactant protein D (SP-D)
28. Pulmonary surfactant and its components inhibit secretion of phosphatidylcholine from cultured rat alveolar type II cells
29. Uptake of lung surfactant subfractions into lamellar bodies of adult rabbit lungs
30. Proteolipid in bovine lung surfactant: Its role in surfactant function
31. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant
32. Surfactant protein D binding to alveolar macrophages
33. Interactions of surfactant protein D with bacterial lipopolysaccharides
34. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant
35. Characterization of Exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses
36. Effect of natural porcine surfactant (Corusurf) on the function of neutrophilic granulocytes
37. Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor of colchicine
38. Surfactant suppresses NF-kappa B activation in human monocytic cells
39. Lung surfactant (LSF) improves gas exchange and histopathology in a model of adult respiratory distress syndrome (ARDS)
40. A synthetic phospholipid-DL surfactant improves lung function in a rat model of ARDS
41. Surface properties in relation to atelectasis and hyaline membrane disease
42. Changing two-year outcome of infants weighing 500 to 999 grams at birth: A hospital study
43. Neonatal mortality risk in relation to gestational age and birth weight
44. Surfactant-associated proteins in tracheal aspirates of infants with respiratory distress syndrome after surfactant therapy
45. Adult respiratory distress syndrome: Animal models
46. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity
47. Inhibition of pulmonary surfactant function by phospholipases
48. Interaction of surfactant mixtures with reactive oxygen and nitrogen species
49. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters tension properties
50. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100]
51. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein
52. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome
53. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure
54. Decreased dipalmitoyl lecithin content found n lung specimens from patients with so-called shock-lung
55. Enhancement of biophysical activity of lung surfactant extracts and phospholipid-apoprotein mixtures by surfactant proteins
56. Densitometric quantification of individual phospholipids. Improvement and evaluation of a method using molybdenum blue reagent for detection
57. Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium
58. Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory distress syndrome
59. Impact of C-reactive protein (CRP) on surfactant function
60. Alteration of surfactant fatty acid profile in acute inflammatory and chronic interstitial lung disease
61. Surfactant abnormalities in patients with respiratory failure after multiple trauma
62. Clinical experience with artificial surfactants
63. Clinical experience with modified natural surfactant
64. Effects of tracheal instillation of natural surfactant in premature lambs. I. Clinical and autopsy findings
65. A European multicenter randomized trial of single dose surfactant therapy for idiopathic respiratory distress syndrome
66. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome
67. Duration and characteristics of treatment with premature lambs with natural surfactant
68. Surfactant and pulmonary blood flow distributions following treatment of premature lambs with natural surfactant
69. Respiratory distress syndrome treated with human surfactant: Radiographic findings
70. Effect of ventilation on surface forces in excised dogs' lungs
71. Effects of surfactant supplement and end-expiratory pressure in lung-lavaged rabbits
72. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: Final analysis of a multicenter, double-blind, comparison with similar trials
73. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome
74. Severe neonatal respiratory distress syndrome treated with the isolated phospholipid fraction of natural surfactant
75. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of Corusurf
76. Bovine surfactant replacement therapy in neonates of less than 30 week's gestation - A randomized controlled trial of prophylaxis versus treatment
77. Surfactant replacement therapy at birth: Final analysis of a clinical trial and comparisons with similar trials
78. Bovine pulmonary surfactant: Chemical and physical properties
79. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome
80. A comparison of four surfactants: In vitro surface properties and responses of preterm lambs to treatment at birth
81. Lung expansion and survival in rabbit neonates treated with surfactant extract
82. Surfactant replacement neonatal RDS
83. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: A multicenter controlled trial
84. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700 to 1350-gram infants with respiratory distress syndrome
85. The physical properties of an effective lung surfactant
86. Dry artificial surfactant and its effect on very premature babies
87. The use of artificial surfactant (ALEC) in the prophylaxis of neonatal respiratory distress syndrome
88. Isolation and characterization of cDNA clones for the 35-kD pulmonary surfactant-associated protein
89. Isolation and characterization of the human pulmonary surfactant apoprotein gene
90. Structural composition of recombinant pulmonary surfactant protein SP-A derived from two human coding sequences: Implications for the chain composition of natural human SP-A
91. Effects of surfactant-associated protein SP-B synthetic analogues on the structure and surface activity of model membrane bilayers
92. Pulmonary surfactant protein B (SP-B): Structure-function relationships
93. Activity of pulmonary surfactant after blocking the associated proteins SP-A and SP-B
94. 4 following surface area cycling and addition of fibrinogen
95. Colfosceril in an infant with adult respiratory distress syndrome
96. The role of pulmonary surfactant in the pathogenesis and therapy of ARDS
97. Surfactant for adults with respiratory failure
98. The adult respiratory distress syndrome: First trials with surfactant replacement
99. A multicentered trial in human sepsis-induced ARDS of an aerosolized synthetic surfactant (Exosurf)
100. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome
101. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome
102. Bovine surfactant therapy for patients with acute respiratory distress syndrome
103. Efficiency of the delivery of aerosolized artificial surfactant in intubated patients with the adult respiratory distress syndrome
104. Principles of inhaled therapy
105. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis
106. 4-surfactant) for acute respiratory distress syndrome
107. 4 surfactant in models of meconium aspiration syndrome
108. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets
109. Surfactant treatment of patients with ARDS may reduce acute lung inflammation
110. Pulmonary surfactant therapy
111. The effect of exogeneous surfactant therapy on lung function following cardiopulmonary bypass
112. Surfactant replacement therapy in late-stage adult respiratory distress syndrome